Allogeneic HCT in MDS/MPN with neutrophilia
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-16 — Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.: Multicenter retrospective cohort (n=85, 8 centers, median follow-up 7.6y) establishes age ≥50, BM blasts ≥5%, Hb <8 g/dL, and TET2/EZH2 mutations as adverse post-HCT predictors, with 5y OS 47% / RFS 37% / CIR 32% / NRM 29% — supporting earlier referral for younger, low-burden patients. (novelty: 3)
Open questions
Related
Contributing findings
Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.
16-jun-2026
novelty 3
per-area 3
introduces